Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
76 Biggest Movers From Yesterday
Gainers
Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.
55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
RenovoRx, Inc. (NASDAQ: RNXT) shares jumped 128% to $12.41. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a potential innovative treatment for pancreatic cancer.
A Look Into Industrials Sector Value Stocks
What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
AerSale Q3 EPS $0.22 Beats $0.20 Estimate, Sales $73.30M Miss $93.50M Estimate
AerSale (NASDAQ:ASLE) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. The company reported quarterly sales of $73.30 million which missed the analyst
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Prescience Point Capital Reports Positive Findings From AerSale’s Public Warrants
Details Research that Shows AerSale's Publicly-Traded Warrants Cannot Be Redeemed Before October 1, 2022 and Are Currently Undervalued
BATON ROUGE, La., Nov. 8, 2021 /PRNewswire/ -- Prescience Point Capital
‘We are long $ASLE. @AerSale is poised to benefit from the greatest re-equipment cycle in the airline industry’s history…’ -Tweet From Investor/Short Seller Prescience Point
https://twitter.com/PresciencePoint/status/1450112640999690247
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.